{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:38:13Z","timestamp":1792730293639,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.expneurol.2026.116000","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:08:52Z","timestamp":1788044932000},"page":"116000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["EAAT1 sustains redox homeostasis and temozolomide resistance through glutamate-dependent regulation of the Keap1\/Nrf2 axis in glioblastoma"],"prefix":"10.1016","volume":"407","author":[{"given":"Lufei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zucheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.expneurol.2026.116000_bb0005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc.2016.114","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"32","key":"10.1016\/j.expneurol.2026.116000_bb0010","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2013.49.6067","article-title":"Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma","volume":"31","author":"Armstrong","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.expneurol.2026.116000_bb0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.vh.2022.09.002","article-title":"The antioxidant glutathione","volume":"121","author":"Averill-Bates","year":"2023","journal-title":"Vitam. Horm."},{"issue":"5","key":"10.1016\/j.expneurol.2026.116000_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112536","article-title":"AKT activation because of PTEN loss upregulates xCT via GSK3beta\/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells","volume":"42","author":"Cahuzac","year":"2023","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.expneurol.2026.116000_bb0025","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/ijc.31985","article-title":"Altered function of the glutamate-aspartate transporter GLAST, a potential therapeutic target in glioblastoma","volume":"144","author":"Corbetta","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.expneurol.2026.116000_bb0030","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1158\/0008-5472.CAN-04-3626","article-title":"The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo","volume":"65","author":"de Groot","year":"2005","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.expneurol.2026.116000_bb0035","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41419-022-05044-9","article-title":"High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1\/MRP1 upregulation","volume":"13","author":"de Souza","year":"2022","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.expneurol.2026.116000_bb0040","first-page":"2051","article-title":"Glutamate transporter 1 expression in human glioblastomas","volume":"25","author":"Donmez Yalcin","year":"2020","journal-title":"J. BUON"},{"key":"10.1016\/j.expneurol.2026.116000_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00357","article-title":"Glutamate transporters in hippocampal LTD\/LTP: not just prevention of excitotoxicity","volume":"13","author":"Goncalves-Ribeiro","year":"2019","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.expneurol.2026.116000_bb0050","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1006\/mcne.2002.1198","article-title":"Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death","volume":"21","author":"Guo","year":"2002","journal-title":"Mol. Cell. Neurosci."},{"issue":"3","key":"10.1016\/j.expneurol.2026.116000_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/0008-5472.CAN-23-0609","article-title":"Neuronal activity promotes glioma progression by inducing proneural-to-mesenchymal transition in glioma stem cells","volume":"84","author":"Guo","year":"2024","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.expneurol.2026.116000_bb0060","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","article-title":"Targeting ferroptosis to iron out cancer","volume":"35","author":"Hassannia","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.expneurol.2026.116000_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1240433","article-title":"Nrf2-mediated therapeutic effects of dietary flavones in different diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"20","key":"10.1016\/j.expneurol.2026.116000_bb0070","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1158\/0008-5472.CAN-11-0782","article-title":"Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.expneurol.2026.116000_bb0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2411241122","article-title":"FAO-fueled OXPHOS and NRF2-mediated stress resilience in MICs drive lymph node metastasis","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.expneurol.2026.116000_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pathmechdis-042524-025950","article-title":"Immunopathology of glioblastoma","volume":"21","author":"Li","year":"2026","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.expneurol.2026.116000_bb0085","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.freeradbiomed.2021.06.028","article-title":"17beta-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma","volume":"172","author":"Lin","year":"2021","journal-title":"Free Radic. Biol. Med."},{"issue":"22","key":"10.1016\/j.expneurol.2026.116000_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225674","article-title":"Excitatory amino acid transporters (EAATs): glutamate transport and beyond","volume":"20","author":"Magi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.expneurol.2026.116000_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-009-9990-5","article-title":"In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines","volume":"97","author":"Marcus","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.expneurol.2026.116000_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121814","article-title":"Molecular mechanisms of ischemia and glutamate excitotoxicity","volume":"328","author":"Neves","year":"2023","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.expneurol.2026.116000_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010351","article-title":"Molecular mechanisms of treatment resistance in glioblastoma","volume":"22","author":"Ou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"39","key":"10.1016\/j.expneurol.2026.116000_bb0110","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1038\/s41388-025-03560-4","article-title":"NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting","volume":"44","author":"Panda","year":"2025","journal-title":"Oncogene"},{"issue":"Supplement_6","key":"10.1016\/j.expneurol.2026.116000_bb0115","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017\u20132021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.expneurol.2026.116000_bb0120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/1570159X13666150122224158","article-title":"Neurodegeneration and the brain tumor microenvironment. [corrected]","volume":"13","author":"Savaskan","year":"2015","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.expneurol.2026.116000_bb0125","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/acs.jproteome.5c00734","article-title":"Mitochondrial metabolic reprogramming along with NRF2\/KEAP1-mediated antioxidant mechanisms drive temozolomide resistance in glioblastoma multiforme","volume":"25","author":"Tomar","year":"2026","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.expneurol.2026.116000_bb0130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12935-019-1040-6","article-title":"Silencing expression of PHF14 in glioblastoma promotes apoptosis, mitigates proliferation and invasiveness via Wnt signal pathway","volume":"19","author":"Wu","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"24","key":"10.1016\/j.expneurol.2026.116000_bb0135","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1523\/JNEUROSCI.19-24-10767.1999","article-title":"Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange","volume":"19","author":"Ye","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2026.116000_bb0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2025.02.040","article-title":"Nrf2 alleviates acute ischemic stroke induced ferroptosis via regulating xCT\/GPX4 pathway","volume":"231","author":"Ye","year":"2025","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.expneurol.2026.116000_bb0145","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/glia.20497","article-title":"DNA methylation dependent silencing of the human glutamate transporter EAAT2 gene in glial cells","volume":"55","author":"Zschocke","year":"2007","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.expneurol.2026.116000_bb0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41420-025-02564-z","article-title":"The Nrf2-HMOX1 pathway as a therapeutic target for reversing cisplatin resistance in non-small cell lung cancer via inhibiting ferroptosis","volume":"11","author":"Zuo","year":"2025","journal-title":"Cell Death Discov."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488626003663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488626003663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:02:13Z","timestamp":1792728133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488626003663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":30,"alternative-id":["S0014488626003663"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2026.116000","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EAAT1 sustains redox homeostasis and temozolomide resistance through glutamate-dependent regulation of the Keap1\/Nrf2 axis in glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2026.116000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116000"}}